CD274 and lung carcinoma: In particular, upfront registration of confounding factors such as concomitant medications (inhaled and systemic corticoids), known predictive factors of ICI efficacy (tumor PD-L1 and mutational status, smoking history, immune-related toxicity), or medical conditions (parasitic infections, atopy, asthma, COPD) is of paramount importance to ascertain (a) role(s) of eosinophils in lung cancer patients treated with ICI.